Table 1

Anti-HIV and HCV mAbs in clinical development.

Compound

Target

Origin

Company

Indication


MAbs against viral antigens


3 mAb cocktail

C2F5, C2G12, and C4E10

Anti-Gp41, anti-glycan structure of Gp120

Human mAb

Rockefeller University

Therapy of HIV infection Phase I/II

P2G12

Anti-glycan structure of Gp120

Human mAb

University of Surrey

European Commission

Prevention of HIV infection Phase I

KD-247

Anti-V3 loop of HIV-1 Env

Humanized mAb

The Chemo-Sero-Therapeutic Research Institute

Therapy of HIV infection Phase I

F105

Anti-Gp120, CD4 binding site

Human mAb

National Institute of Allergy and Infectious Diseases (NIAID)

Therapy of HIV infection Phase I

MBL-HCV1

Anti-E2

Human mAb

MassBiologics

Prevention of liver reinfection with HCV after transplantation Phase II


MAbs against host antigens


IBALIZUMAB

Anti-CD4 receptor

Humanized mAb

TaiMed Biologics/Tanox

Therapy of HIV infection Phase I/II

PRO-140

Anti-CCR5 receptor

Humanized mAb

Progenics/PDL

Therapy of HIV infection Phase I/II

CCR5mAb004

Anti-CCR5 receptor

Human mAb

Human Genome Sciences

Therapy of HIV infection Phase I

BAVITUXIMAB

Anti-phosphatidyl serine.

Chimeric mAb

Peregrine Pharmaceuticals

Therapy of HIV/HCV co-infection Phase II

Therapy of chronic HCV infection co-administrated with ribavirin Phase II


Immunomodulatory mAbs


TREMELIMUMAB

CP 675,206

Anti-CTLA-4

Humanized mAb

Pfizer

Therapy of HIV infection Phase I (study withdrawn prior to enrollment)

Therapy of advanced HCC in HCV infected patient Phase II

CT-011

Anti-PD-1

Humanized mAb

CureTech

Therapy of chronic HCV infection Phase I/II

BMS 936558

(MDX1106)

Anti-PD-1

Human mAb

Bristol-Myers Squibb/Medarex

Therapy of chronic HCV infection Phase I


Flego et al. BMC Medicine 2013 11:4   doi:10.1186/1741-7015-11-4

Open Data